MeiraGTx Holdings (MGTX) Net Cash Flow Growth (1y) (2018 - 2025)
MeiraGTx Holdings (MGTX) Net Cash Flow Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 53.46% |
| 10 | MeiraGTx Holdings | 998.14 Mn | 932.21 Mn | - | 351.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 351.21% |
| Sep 30, 2025 | -154.96% |
| Jun 30, 2025 | -104.81% |
| Mar 31, 2025 | -244.83% |
| Dec 31, 2024 | -131.47% |
| Sep 30, 2024 | 183.23% |
| Jun 30, 2024 | -180.06% |
| Mar 31, 2024 | 77.41% |
| Dec 31, 2023 | 86,848.65% |
| Sep 30, 2023 | -167.24% |
| Jun 30, 2023 | 157.31% |
| Mar 31, 2023 | -102.35% |
| Dec 31, 2022 | 101.41% |
| Sep 30, 2022 | 245.39% |
| Jun 30, 2022 | -57.09% |
| Mar 31, 2022 | -141.97% |
| Dec 31, 2021 | -117.70% |
| Sep 30, 2021 | -83.26% |
| Jun 30, 2021 | -68.42% |
| Mar 31, 2021 | 40.66% |